Erlotinib for Japanese Patients with Activating EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Combined Analyses from Two Phase II Studies

References

• Jemal A , BrayF, CenterMM, FerlayJ, WardE, FormanD. Global cancer statistics. CA Cancer J. Clin.61(2), 69–90 (2011).
   PubMed Web of Science ®Google Scholar
• GLOBOCAN . Estimated cancer incidence, mortality and prevalence worldwide in 2012 (2015). http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
   Google Scholar
• Midha A , DeardenS, McCormackR. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am. J. Cancer Res.5(9), 2892–2911 (2015).
   PubMed Web of Science ®Google Scholar
• National Clinical Cancer Network . NCCN Clinical Practice Guidelines for non-small-cell lung cancer. V6.2015. www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
   Google Scholar
• Reck M , PopatS, ReinmuthNet al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.25(Suppl. 3), iii27–iii39 (2014).
   PubMed Web of Science ®Google Scholar
• Sgambato A , CasaluceF, MaionePet al. The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non-small-cell lung cancer patients harboring EGFR mutation. Curr. Med. Chem.19(20), 3337–3352 (2012).
   PubMed Web of Science ®Google Scholar
• Zhou C , WuYL, ChenGet al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol.12(8), 735–742 (2011).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T , MoritaS, YatabeYet al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol.11(2), 121–128 (2010).
   PubMed Web of Science ®Google Scholar
• Wu YL , ZhouC, HuCPet al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised Phase 3 trial. Lancet Oncol.15(2), 213–222 (2014).
   PubMed Web of Science ®Google Scholar
• Goto K , NishioM, YamamotoNet al. A prospective, Phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer82(1), 109–114 (2013).
   PubMed Web of Science ®Google Scholar
• Seto T , KatoT, NishioMet al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, Phase 2 study. Lancet Oncol.15(11), 1236–1244 (2014).
   PubMed Web of Science ®Google Scholar
• Costa C , MolinaMA, DrozdowskyjAet al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized Phase III EURTAC trial. Clin. Cancer Res.20(7), 2001–2010 (2014).
   PubMed Web of Science ®Google Scholar
• Wu YL , ZhouC, LiamCKet al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the Phase III, randomized, open-label, ENSURE study. Ann. Oncol.26(9), 1883–1889 (2015).
   PubMed Web of Science ®Google Scholar
• Markman M . Genetics of non-small-cell lung cancer. Medscape, 2014. http://emedicine.medscape.com/article/1689988-overview.
   Google Scholar
• Froudarakis ME . Pleural effusion in lung cancer: more questions than answers. Respiration83(5), 367–376 (2012).
   PubMed Web of Science ®Google Scholar
• Tsai TH , SuKY, WuSGet al. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. Eur. Respir. J.39(3), 677–684 (2012).
   PubMed Web of Science ®Google Scholar
• Morgensztern D , WagarS, SubramanianJ, TrinkausK, GovindanR. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer. J. Thorac. Oncol.7(10), 1485–1489 (2012).
   PubMed Web of Science ®Google Scholar
• Zou J , BellaAE, ChenZet al. Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: implication of cancer biological behaviour regulated by EGFR mutation. J. Int. Med. Res.42(5), 1110–1117 (2014).
   PubMed Web of Science ®Google Scholar
• Naumov GN , NilssonMB, CasconeTet al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin. Cancer Res.15(10), 3484–3494 (2009).
   PubMed Web of Science ®Google Scholar
• Bradshaw M , MansfieldA, PeikertT. The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr. Oncol. Rep.15(3), 207–216 (2013).
   PubMed Web of Science ®Google Scholar
• Tsai MF , ChangTH, WuSGet al. EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway. Sci. Rep.5, 13574 (2015).
   PubMed Web of Science ®Google Scholar
• Hata A , KatakamiN, YoshiokaHet al. Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKI: poorer prognosis associated with T790M-negative status and leptomeningeal metastases. Anticancer Res.35(2), 1025–1031 (2015).
   PubMed Web of Science ®Google Scholar
• Omuro AM , KrisMG, MillerVAet al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer103(11), 2344–2348 (2005).
   PubMed Web of Science ®Google Scholar
• Heon S , YeapBY, LindemanNIet al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small-cell lung cancer with EGFR mutations. Clin. Cancer Res.18(16), 4406–4414 (2012).
   PubMed Web of Science ®Google Scholar